Turn's technologies increase ability of T cells to kill cancer in preclinical studies
Oct. 25, 2022
Turn Biotechnologies Inc. has presented interim preclinical data that demonstrates treating T cells with its proprietary technologies can significantly increase their ability to kill cancer.
